MedTrace Logo

Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate

NCT04925778 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-11-18

No results posted yet for this study

Summary

This is an open-label, multicenter, observational study evaluating GI symptoms in relapsing-remitting multiple sclerosis (RRMS) patients who switch from dimethyl fumarate (DMF) to Bafiertam®.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

monomethyl fumarate

Patients will be prescribed 190 mg (two 95 mg capsules) self-administered twice/day,

Sponsors & Collaborators

  • Banner Life Sciences LLC

    lead INDUSTRY

Principal Investigators

  • Thomas W Lategan, D.Phil. · Banner Life Sciences LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-08-30
Completion
2022-09-29
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04925778 on ClinicalTrials.gov